Seres Therapeutics Investor Presentation May 2025 Disclaimers 2 Seres Therapeutics, Inc. © 2025 2 Transforming patient outcomes using proprietary consortia of live biotherapeutics Strong Foundation Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including s ...

The Company plans to submit a Phase 2 trial protocol for SER-155 in allo-HSCT to the FDA in the coming weeks and is actively seeking partners to support continued clinical development. Presentation Details Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or th ...

Seres Therapeutics (MCRB) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Seres Therapeutics First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference o ...

Recent Highlights In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction ...

Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical devel ...

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit ...

Core Viewpoint - Zymeworks Inc. has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development, enhancing its leadership team to advance its clinical-stage oncology portfolio and diversify into autoimmune and inflammatory diseases [1][2]. Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune diseases [1][4]. - The company utilizes proprietary technologies to engineer and develop differentiated antibody-based therapeutic candidates, including zanidatamab, a HER2-targeted bispecific antibody [4][5]. Leadership Changes - Dr. Sabeen Mekan, with 18 years of experience in hematology and oncology, will play a crucial role in formulating the clinical development strategy for Zymeworks' oncology portfolio [2][3]. - Dr. Jeff Smith continues as Executive Vice President & Chief Medical Officer, focusing on R&D in autoimmune and inflammatory diseases [1][2]. - Barbara Schaeffler has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith [1]. Clinical Development Focus - The expanded clinical development team aims to enhance the focus on progressing Zymeworks' clinical-stage solid tumor portfolio while diversifying into autoimmune and inflammatory diseases [2]. - Dr. Mekan expressed commitment to addressing unmet needs in various cancer types through next-generation antibody-drug conjugates and multispecific antibody therapeutics [2][3]. Pipeline and Regulatory Progress - Zymeworks has received FDA accelerated approval for Ziihera® (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer [4]. - The company is advancing a robust pipeline, with Phase 1 studies for ZW171 and ZW191 actively recruiting and an investigational new drug application for ZW251 planned for mid-2025 [5].

Core Viewpoint - Zymeworks Inc. is set to report its first quarter 2025 financial results on May 8, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update [1][2] Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving treatment for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases [3] - The company utilizes its proprietary Azymetric™ technology to engineer and develop zanidatamab, a HER2-targeted bispecific antibody [3] - Zymeworks has exclusive agreements with BeiGene and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in different regions [3] - The U.S. FDA has granted accelerated approval for Ziihera® (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive second-line biliary tract cancer, marking it as the first dual HER2-targeted bispecific antibody approved for this indication in the U.S. [3] - Zanidatamab is currently under regulatory review in the EU and China and is being evaluated in multiple global clinical trials for various HER2-expressing cancers [3] - Zymeworks is advancing a robust pipeline of product candidates, with ongoing Phase 1 studies for ZW171 and ZW191, and plans for an investigational new drug application for ZW251 in mid-2025 [3] - The company has established strategic partnerships with global biopharmaceutical companies to further leverage its therapeutic platforms [3]

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell - Executive Vice President and Chief Financial Officer Chris McChalic ...